Agilent Technologies Inc
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Agilent Technologies Inc (A). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Agilent CrossLab | $1.36B 21.5% | $1.45B 21.2% · +6.8% | $2.66B 38.9% · +82.9% | $2.75B 42.2% · +3.4% | $2.91B 41.9% · +5.9% |
| Life Sciences and Diagnostics Markets | – | – | $2.78B 40.7% | $2.47B 37.9% · -11.3% | $2.73B 39.2% · +10.5% |
| Applied Markets | – | – | $1.40B 20.4% | $1.30B 19.9% · -7.2% | $1.31B 18.9% · +1.3% |
| Life Sciences and Applied Markets | $3.66B 58.0% | $3.63B 53.0% · -0.9% | – | – | – |
| Diagnostics and Genomics | $1.30B 20.5% | $1.77B 25.8% · +36.3% | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.